Abbott ABT Medical Devices — Remaining performance obligations
Other segment segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Abbott in its filing.
Tagged under the XBRL concept us-gaap:RevenueRemainingPerformanceObligation.
The source filing: Abbott’s 10-Q, filed July 28, 2026.
- Filed
- Jul 28, 2026, 4:02 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001628280-26-050134
As of June 30, 2026, the estimated revenue expected to be recognized in the future related to performance obligations that are unsatisfied (or partially unsatisfied) was $6.2 billion in the Diagnostic Products segment, $455 million in the Medical Devices segment, and $243 million in the Established Pharmaceuticals Products segment. Abbott expects to recognize revenue on approximately 52 percent of these remaining performance obligations over the next 24 months, approximately 18 percent over the subsequent 12 months, and the remainder thereafter.
Item 1. Financial Statements and Supplementary Data
FAQ
- What is Abbott's medical devices — remaining performance obligations?
- Abbott (ABT) reported medical devices — remaining performance obligations of $455M in Q2 2026.
- How has Abbott's medical devices — remaining performance obligations changed year-over-year?
- Abbott's medical devices — remaining performance obligations increased by 6.6% year-over-year, from $427M to $455M.
- What is the long-term trend for Abbott's medical devices — remaining performance obligations?
- Over 4 years (2021 to 2025), Abbott's medical devices — remaining performance obligations has grown at a 0.5% compound annual growth rate (CAGR), from $1.69B to $1.73B.
- What does medical devices — remaining performance obligations mean?
- Represents the aggregate amount of the transaction price allocated to performance obligations that are unsatisfied or partially unsatisfied at the end of the reporting period. This reflects future revenue under existing long-term contracts or service agreements for medical devices. It provides visibility into the stability of future revenue streams.
Ask your AI about Abbott's medical devices — remaining performance obligations.
Connect your AI assistant and compare segments, right in your chat.
